Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Sponsor

Sunnybrook Health Sciences Centre (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT02036086

Collaborator

(none)

Enrollment

Locations

Arm

Anticipated Duration (Months)

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will evaluate the clinical and pathological response to vemurafenib and cobimetinib in the neoadjuvant treatment of patients with histologically confirmed, BRAF V600 mutation-positive Stage IIIB and C melanoma. 20 patients will be treated with vemurafenib and cobimetinib for 2 months. Then they will be assessed for surgery. Patients will undergo surgery and subsequently resume taking vemurafenib and cobimetinib after recovery from surgery. Patients will undergo radiation therapy if appropriate then continue vemurafenib and cobimetinib. The maximum treatment period is 12 months. After 12 months of treatment, patients will be followed for disease recurrence and survival during for a total of 5 years.

Condition or Disease	Intervention/Treatment	Phase
Melanoma	Drug: Vemurafenib Drug: Cobimetinib	Phase 2

Detailed Description

At Screening: Assessments will include CT or MRI of the brain, CT of chest, abdomen and pelvis, dermatology assessment, head and neck exam, pelvic and anal exam, ophthalmology exam, electrocardiogram (ECG), echocardiogram (ECHO) or multigated acquisition (MUGA) scan, a history and physical exam. A core biopsy will be performed within 14 days of study entry.

During Treatment: The maximum treatment period is 12 months. Patients will be assessed monthly while on treatment. Assessments performed will include vital signs assessment and physical exam, dermatology exam, ophthalmology exam, echocardiogram (ECHO) or multigated acquisition (MUGA) scan, electrocardiogram (ECG), safety blood tests, pelvic and anal exam.

Follow-up after treatment: Patients will be followed for 5 years. Radiology exams will be done to assess for disease. Other assessments performed include vital signs assessment and physical exam, dermatology exam, include echogram (ECHO) or multigated acquisition (MUGA) scans.

Study Design

Study Type:

Interventional

Actual Enrollment :

24 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases.

Actual Study Start Date :

Aug 1, 2015

Anticipated Primary Completion Date :

Oct 1, 2022

Anticipated Study Completion Date :

Oct 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Vemurafenib, pill, twice daily Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily	Drug: Vemurafenib Drug Other Names: Zelboraf Drug: Cobimetinib Drug Other Names: GDC-0973

Arm

Intervention/Treatment

Experimental: Vemurafenib, pill, twice daily

Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily

Drug: Vemurafenib

Drug

Other Names:

Zelboraf

Drug: Cobimetinib

Drug

Other Names:

GDC-0973

Outcome Measures

Primary Outcome Measures

The feasibility of treating patients with unresectable melanoma and palpable lymph node metastases that harbor the BRAF mutation with neoadjuvant vemurafenib. [24 months]

Secondary Outcome Measures

Resectability rates post vemurafenib therapy [5 years]
Local-regional recurrence rates after treatment with neo-adjuvant vemurafenib. [5 years]
Time to distant metastases and Distant Metastatic Free Survival (DMFS). [5 years]
Disease Free Survival (DFS) and Overall Survival (OS). [5 years]
Immunohistochemical correlates of tumor response. [5 years]
Safety and tolerability of vemurafenib in the neoadjuvant setting [5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Naïve to treatment for locally advanced unresectable disease (Stage IIIB and C). Prior adjuvant therapy (including immunotherapy, e.g., ipilimumab) is allowed if prior to nodal recurrence and ≥ 3 months have elapsed from the last day of adjuvant therapy to start of study treatment2. Biopsy proven unresected melanoma with palpable regional lymph node.
Biopsy proven unresected melanoma patients with palpable regional lymph node metastases, presenting with AJCC stage IIIB-C or with recurrent regional lymphadenopathy that are not suitable or not prefered for surgcal intervention.
BRAF V600 mutation positive.
Eastern Cooperative Oncology Group performance status of 0 or 1.
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Adequate hematologic, renal and liver function within 7 days prior to the first dose of vemurafenib and cobimetinib.
Agree to always use an effective form(s) of contraception beginning from the informed consent signature date until at least 6 months after completion of study therapy.
Negative serum pregnancy test within 14 days prior to start of treatment in women of childbearing potential only.
Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

Exclusion Criteria:

Cannot have received any prior therapy for the current recurrence or nodal disease. Previous adjuvant immunotherapy is allowed if prior to nodal recurrence and ≥ 3 months have elapsed from the last day of adjuvant therapy to start of study treatment.
History of prior RAF or MEK pathway inhibitor treatment.
Active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past 3 years are excluded; except for patients with resected melanoma, resected basal cell carcinoma (BCC), resected cutaneous squamous cell carcinoma (SCC), resected melanoma in situ, resected carcinoma in-situ of the cervix, and resected carcinoma in-situ of the breast.
Evidence of distant metastatic disease.
History of clinically significant liver disease (including cirrhosis), current alcohol abuse, or known infection with Human Immunodeficiency Virus (HIV), hepatitis B virus, or hepatitis C virus.
Active infection or chronic infection requiring chronic suppressive antibiotics.
Pregnant or breastfeeding at the time of enrollment.
Active autoimmune disease (e.g., systemic lupus erythematosus, autoimmune vasculitis, inflammatory bowel disease [Crohn's disease and ulcerative colitis]).
Acromegaly
History of malabsorption or other clinically significant metabolic dysfunction.
Any other serious concomitant medical condition that would compromise safety or compromise the ability to participate in the study.
Requires a concomitant medication or dietary supplement that is prohibited during the study.
Unwillingness or inability to comply with study and follow-up procedures.
Current, recent (within 28 days of enrolment) or planned use of any investigational product outside of this study.
The following foods or supplements are prohibited at least 7 days prior to initiation of and during study treatment:
St. John's wort or hyperforin
Grapefruit juice
History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment / central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration.
Currently are known to have the following conditions:
Uncontrolled glaucoma with intra-ocular pressures with > 21 mmHg
Retinal venous occlusion (RVO)
Hypertensive retinopathy
Clinically significant cardiac dysfunction, including the following:
Current unstable angina
Current symptomatic congestive heart failure of New York Heart Association class 2 or higher
History of congenital long QT syndrome or QTcF > 450 msec at baseline or uncorrectable abnormalities in serum electrolytes (sodium, potassium, calcium, magnesium, phosphorus).
Current uncontrolled hypertension ≥Grade 2 (patients with a history of hypertension controlled with anti-hypertensives to ≤ Grade 1 are eligible).
Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower.
Palliative radiotherapy or major surgery within 14 days prior to first dose of study treatment.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The Ottawa Hospital - General Campus	Ottawa	Ontario	Canada	K1H 8L6
2	Sunnybrook Health Sciences Centre	Toronto	Ontario	Canada	M4N 3M5
3	Royal Victoria Hospital	Montreal	Quebec	Canada	H3A 1A1